BPC 157 tablets (50 count)

BPC-157 tablets catalog details

BPC-157 tablets are listed here in a 50-count format. USA Eternal Peptides keeps this entry separate from BPC-157 vial products so buyers can distinguish item count, format and the source product documentation. The tablet form is not presented as an approved medicine or supplement.

Count and format belong together in the tablet record

The listing is described by a tablet count, whereas the vial pages are named by a milligram quantity. Those fields measure different aspects of a product. Confirm the format and any per-item specification from relevant documentation rather than inferring it from the count alone.

Catalog comparisons for this product

Compare the separately identified records for BPC-157 10mg, BPC-157 5mg. Each link leads to its own named product and quantity; it does not recommend combining or substituting materials.

Tablets should not be renamed capsules for a keyword

The uploaded ranking export contains capsule-related searches, but this product is labeled tablets. That distinction remains in the title and description. The related vial entries provide catalog comparisons without asserting that a different format has the same properties or intended use.

What is BPC 157?

BPC-157 (body protection compound-157) is a synthetic pentadecapeptide modeled after a partial sequence of a gastric protein known as BPC. It was first characterized as a stable peptide fragment present in gastric juice.

Preclinical research-largely in vitro and in rodent injury models-indicates that BPC-157 may influence multiple repair-related processes, including angiogenesis, extracellular-matrix remodeling, and cytoprotection in tendon, muscle, bone, and gastrointestinal tissues. These findings, however, are not validated in controlled human trials, and the current evidence base remains almost entirely preclinical.

How BPC-157 Works (Mechanism of Action)

As per studies and existing in the field, BPC-157 exhibits pleiotropic activity, interacting with multiple regulatory pathways rather than targeting a single receptor. These mechanistic insights come predominantly from cellular assays and animal studies.

Angiogenesis and VEGF/VEGFR2

Studies indicate that BPC-157 can modulate vascular endothelial growth factor (VEGF) expression and VEGFR2 activity, stimulating Akt–eNOS pathways linked to endothelial stabilization, angiogenesis, and tissue revascularization[1]. 

This means BPC-157 may help blood vessels grow and repair themselves more efficiently. By promoting these vascular processes, tissues that have been damaged or are healing-such as muscles, tendons, or gut lining-may receive improved blood flow, oxygen, and nutrients. This enhanced microcirculation can support faster recovery and maintain the health of endothelial cells that line the blood vessels, which is a critical component of overall tissue repair and regeneration.

Nitric-oxide modulation and cytoprotection

Studies suggest that BPC-157 can counteract harmful nitric oxide (NO) overproduction while supporting normal physiological NO signalling, contributing to cytoprotection in severe injury models[2].

That means BPC-157 may help maintain a healthy balance of nitric oxide in the body, which is important for blood flow, immune response, and tissue function. However, excessive NO levels can damage cells and tissues, so regulating NO may help protect cells from injury, reduce tissue stress, and support the healing of damaged muscles, tendons, or organs.

This balanced effect is especially important during severe injury, where uncontrolled NO could otherwise worsen tissue damage.

Anti-inflammatory signalling and ECM interactions

According to preclinical models, BPC-157 may affect inflammation and help remodel the extracellular matrix, which is the scaffold supporting tissues. By interacting with proteins like FAK and paxillin, it may speed up cell migration and tissue repair, helping wounds or damaged tissues recover more efficiently[3].

Gastrointestinal mucosal protection

BPC-157 has been shown in animal studies to demonstrate regenerative properties to the lining of the stomach and intestines. It can reduce damage from ulcer-causing agents and promote mucosal repair, supporting the integrity of the gut barrier[4]. This effect may help protect digestive tissues and maintain normal gastrointestinal function.

CNS-related findings

Some preclinical studies suggest BPC-157 may have neuroprotective effects. It appears to reduce neuroinflammation and support the health of blood vessels in the brain, which may help maintain tissue function after injury or stress[5]. These findings are mostly from animal models, so clinical relevance in humans is not yet established.

BPC-157 Research Value

BPC-157 shows a variety of research benefits, especially in studying tissue regeneration, inflammatory response, and microvascular stability.

Multi-pathway activity relevant to tissue repair

Preclinical work shows consistent effects across models of wound healing, tendon or ligament injury, muscle damage, and GI irritation. Researchers value it because it seems to influence several systems at once – inflammation, angiogenesis, nitric oxide signalling, and ECM remodeling – giving a broader view of how these pathways interact during tissue recovery.

Angiogenesis and vascular stability

Rodent studies suggest BPC-157 may support capillary repair and microvascular stability[7]. This makes it useful for studying how blood flow changes affect healing, especially in ischemic or mechanically stressed tissues.

Mucosal protection and epithelial integrity

Early research focused on the GI tract, where BPC-157 repeatedly showed protective effects against ulceration and toxin-induced damage[7]. As a result, it’s often used to explore how the gut lining maintains barrier function under stress.

Systemic coordination of healing

Some studies highlight tissue improvements distant from the injury site, which has led researchers to use BPC-157 as a model for investigating whole-body healing responses rather than isolated, single-tissue effects.

BPC-157 Peptide Characteristics

Handling & Storage Guidelines

• Store sealed at room temperature or 35.8°F – 46.4°F (2–8°C).
• Protect from humidity.
• Dissolve following protocols validated for tablet-based research delivery systems (e.g., solvent screening, dissolution timing, filtered solutions).
• Follow institutional biosafety and chemical-handling requirements.

BPC-157 Lyophilized Powder vs BPC-157 Tablets

The primary differences between the lyophilized powder and oral forms of BPC-157 relate to delivery, stability, and experimental control rather than mechanism. Lyophilized powder is typically favored in laboratory settings because it allows precise reconstitution, flexible concentration ranges, and greater control over experimental variables.

On the other hand, the tablets introduce additional considerations such as excipients, fixed dosing, and altered exposure dynamics, which may influence how the peptide is studied but do not represent a distinct or enhanced mechanism of action.

COA / Quality Assurance

USA Eternal Peptides makes certificates of analysis available for every product batch. Each COA typically documents peptide identity (HPLC and/or mass spectrometry), purity analysis, endotoxin levels, sterility testing (where applicable), and specific storage recommendations for that batch.

As a reputable peptide supplier, USA Eternal Peptides works with Janoshik and other leading testing labs for results you can trust.

You can check that the COA corresponds to the exact lot you ordered, since USA Eternal Peptides  keeps these records on our Lab Tests page to promote transparency, traceability, and compliance requirements.

Legal / Regulatory Disclaimer

BPC-157 from USA Eternal Peptides is sold exclusively for research purposes and not for human or veterinary use, clinical administration, or therapeutic applications. The compound is not approved by any regulatory authority, and its safety or effectiveness in humans has not been established.

As the buyer, you are responsible for ensuring compliance with all local laws, institutional biosafety policies, and research-use regulations. Any misrepresentation of intended use may lead to regulatory or legal consequences.

Scientific References

1. Hsieh MJ, Lee CH, Chueh HY, Chang GJ, Huang HY, Lin Y, Pang JS. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020 Oct 13;10(1):17078.

https://pmc.ncbi.nlm.nih.gov/articles/PMC7555539/ 

2. Sikiric P, Seiwerth S, Skrtic A, Staresinic M, Strbe S, Vuksic A, Sikiric S, Bekic D, Soldo D, Grizelj B, Novosel L, Beketic Oreskovic L, Oreskovic I, Stupnisek M, Boban Blagaic A, Dobric I. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide’s Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals 2025, 18, 185. Pharmaceuticals (Basel). 2025 Sep 28;18(10):1450.

https://pmc.ncbi.nlm.nih.gov/articles/PMC12567428/ 

3. Cushman CJ, Ibrahim AF, Smith AD, Hernandez EJ, MacKay B, Zumwalt M. Local and Systemic Peptide Therapies for Soft Tissue Regeneration: A Narrative Review. Yale J Biol Med. 2024 Sep 30;97(3):399-413.

https://pmc.ncbi.nlm.nih.gov/articles/PMC11426299/ 

4. Sikiric P, Hahm KB, Blagaic AB, Tvrdeic A, Pavlov KH, Petrovic A, Kokot A, Gojkovic S, Krezic I, Drmic D, Rucman R, Seiwerth S. Stable Gastric Pentadecapeptide BPC 157, Robert’s Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye’s Stress Coping Response: Progress, Achievements, and the Future. Gut Liver. 2020 Mar 15;14(2):153-167.

https://pmc.ncbi.nlm.nih.gov/articles/PMC7096228/ 

5. Vukojevic J, Milavić M, Perović D, Ilić S, Čilić AZ, Đuran N, Štrbe S, Zoričić Z, Filipčić I, Brečić P, Seiverth S, Sikirić P. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022 Mar;17(3):482-487.

https://pmc.ncbi.nlm.nih.gov/articles/PMC8504390/ 

6. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025 Dec;18(12):611-619.

https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/ 

7. Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025 Jul 31:15563316251355551.
   https://pmc.ncbi.nlm.nih.gov/articles/PMC12313605/

Documentation for BPC-157 tablets

Open the product COA images to inspect the original issuer, tested sample and batch details. The Eternal Peptides COA library provides a broader document index. These recovered reports concern historical source samples and do not certify a new lot supplied by USA Eternal Peptides.

Do searches for BPC-157 capsules establish this product’s format?

No. The product is identified as a 50-count tablet listing. Search wording should not override the actual catalog name or specification.

The selected BPC-157 tablets quantity, current price and availability appear in this product record. Review shipping and returns information and payment options before submitting an order. Listed amounts are pack quantities, not dosing instructions. All materials are for laboratory research only, not for human or animal consumption.

Original Eternal Peptides reports retain their tested supplier and batch identity. USA Eternal Peptides is independent; these reports do not certify its inventory.